✦ LIBER ✦

Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy

✍ Scribed by Francisco A Conde; Linda Sarna; Roberta K Oka; Donna L Vredevoe; Matthew B Rettig; William J Aronson

Book ID: 116944263
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 134 KB
Volume: 64
Category: Article
ISSN: 0090-4295
DOI: 10.1016/j.urology.2004.03.036

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pretreatment prostate-specific antigen v

Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy

✍ David Palma; Scott Tyldesley; Tom Pickles; for the Prostate Cohort Outcomes Init 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

## Abstract ## BACKGROUND In men with prostate cancer, pretreatment prostate‐specific antigen (PSA) velocity (PSAV) has been demonstrated as a predictor of biochemical and survival outcomes in patients undergoing radical prostatectomy (RP). The utility of pretreatment PSAV in predicting outcomes a

Body mass index is not a prognostic mark

Body mass index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men treated with brachytherapy

✍ Joep G.H. Van Roermund; Karel A. Hinnen; Jan J. Battermann; J. Alfred Witjes; J. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB